Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2011

View Archived Issues

Preclinical and clinical phase I/II data presented on GSK-573719 for COPD

Novel SMYD2 inhibitor identified at AstraZeneca

Novel pan-Aurora kinase inhibitor is active against drug-resistant cancer cells

Novel CO-releasing rhenium complexes developed at Swiss university

Phosphagenics to advance development of twice-weekly oxycodone patch

Enrollment complete in pediatric Xerecept trial

Incozen Therapeutics describes new PI3K-delta inhibitor

Creabilis raises funds for development of CT-327

Scientists at GSK prepare new lysophospholipid S1P1 receptor agonists

Novel neuroprotective agents patented

New saRNA molecules claimed by University of California scientists

Novel PP1 inhibitors synthesized

EntreMed reports encouraging phase II results on ENMD-2076

Fibrocell Science launches laViv in U.S.

InSite Vision releases phase II pharmacokinetic data on BromSite

Intellect Neurosciences and ViroPharma enter licensing agreement for OX-1

CalciMedica presents novel protein orai-1 inhibitors

NuPathe reports encouraging data from migraine patch trial

Gliknik receives SBIR contract to advance stradobodies

Merck Serono and Ono Pharmaceutical collaborate on MS drug and cancer vaccine

G-Zero Therapeutics receives NIH grant for studies in radiation exposure

Karo Bio enrolls first patient in AKKA study

Neurocrine and Abbott reach second milestone in elagolix collaboration

First patients dosed with Xiaflex in Dupuytren's contracture multicord study

Cariprazine study meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...